Status:
COMPLETED
A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus
Lead Sponsor:
Eli Lilly and Company
Conditions:
Diabetes Mellitus, Type 1
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
Two forms of insulin lispro (LY900014 and Humalog®) and two forms of insulin aspart (NovoRapid® and Fiasp®) will be given to trial participants with diabetes mellitus type 1 by injection under the ski...
Eligibility Criteria
Inclusion
- Are male or female participants with Type 1 Diabetes Mellitus (T1DM) for at least 1 year
- Have a body mass index (BMI) of 18.5 to 35.0 kilogram per meter square (kg/m²)
- Have a glycated hemoglobin (HbA1c) less than (\<)9.0 percent (%)
- Have had no episodes of severe hypoglycaemia in the last 6 months
Exclusion
- \- Have a history or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine (apart from T1DM), hematological, or neurological disorders capable of significantly altering the absorption, metabolism or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data
Key Trial Info
Start Date :
March 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 14 2018
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03449433
Start Date
March 15 2018
End Date
August 14 2018
Last Update
April 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Profil Institut für Stoffwechselforschung
Neuss, North Rhine-Westphalia, Germany, 41460